Yes. A single-agent trial runs on the same engine with one candidate drug instead of several. Every adverse event still gets a CTCAE grade against the trial's version, a MedDRA code, and a WHO-UMC and Kramer assessment for the study drug, and the engine still weighs alternative causes such as the disease itself, concomitant medications and known comorbidities. Citation, clinician review and 21 CFR Part 11 signature work exactly as they do for combination regimens.
More on multi drug attribution.
- What is multi-drug attribution?
- How does Burna AI compute adverse event attribution?
- What are the WHO-UMC causality categories and the Kramer algorithm?
- What is dechallenge and rechallenge?
- Which oncology regimens does Burna AI cover?
- How does Burna AI handle protocols where the trial drug profile is sensitive sponsor IP?